Cystic fibrosis gene therapy - CFTR-cationic liposome complex

Drug Profile

Cystic fibrosis gene therapy - CFTR-cationic liposome complex

Alternative Names: CFTR gene-cationic liposome complex

Latest Information Update: 07 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial sources
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Cystic fibrosis in USA (unspecified route)
  • 19 Jul 2001 No-Development-Reported for Cystic fibrosis in United Kingdom (Intranasal)
  • 19 Jul 2001 Preclinical development for Cystic fibrosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top